The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.

Inclusion Criteria:

• Participant must have histologically or cytologically confirmed adenocarcinoma of the prostate.
• Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
• Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL at Screening
• Participant must have progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)

Exclusion Criteria:

• Participant must not have history of brain metastases.
• Participant must not have impaired cardiac function or clinically significant cardiac disease.
• Participant must not have any significant medical condition, including active or uncontrolled infection, psychiatric illness, or the presence of laboratory abnormalities, which places the participant at unacceptable risk or prevent participation in the study based on Investigator assessment.

Other protocol-defined inclusion/exclusion criteria apply

BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

See Plan Description

See Plan Description